SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-005188
Filing Date
2021-01-29
Accepted
2021-01-29 09:00:19
Documents
3
Period of Report
2021-01-29

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea134203-6k_nlspharma.htm 6-K 17507
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS LTD. ANNOUNCES PRICING OF $20.0 MILLION ea134203ex99-1_nlspharma.htm EX-99.1 12378
3 GRAPHIC ex99-1_001.jpg GRAPHIC 11641
  Complete submission text file 0001213900-21-005188.txt   47030
Mailing Address ALTER POSTPLATZ 2 STANS V8 CH-6370
Business Address ALTER POSTPLATZ 2 STANS V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 21568344
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences